Outcomes of curative nephrectomy against renal cell carcinoma based on a central pathological review of 914 specimens from the era of cytokine treatment
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490503 | ||
| 003 | CHVBK | ||
| 005 | 20210128100505.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0840-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0840-5 | ||
| 245 | 0 | 0 | |a Outcomes of curative nephrectomy against renal cell carcinoma based on a central pathological review of 914 specimens from the era of cytokine treatment |h [Elektronische Daten] |c [Noriyuki Ito, Shinsuke Kojima, Satoshi Teramukai, Yoshiki Mikami, Osamu Ogawa, Tomomi Kamba] |
| 520 | 3 | |a Background: The purpose of this study was to determine the state of modern practice with regard to renal cell carcinoma (RCC) outcomes and to assess the effects on survival of such clinical and pathological factors such as histological subtype (HS) and nuclear grade by conducting a central pathological review based on the current World Health Organization classification and the staging system of the American Joint Committee on Cancer/Union for International Cancer Control. Methods: We collected glass slides and clinical data sets for 914 cases of RCC treated with curative nephrectomy from 1995 to 2000. Overall (OS), cancer-specific (CSS), and relapse-free (RFS) survival were compared for HS and nuclear grades determined by a central pathology review board comprising 5 board-certified pathologists, pathological staging, and a variety of clinical factors. Results: The 5 and 7-year CSS in this study were 96 and 93%, respectively, values superior to those reported in Western countries. Concordance between the original and reviewed HS and nuclear grades were 90.9 and 21.1%, respectively. HS correlated with OS (P=0.043) but was not an independent prognostic factor in the multivariate analysis (P=0.820). Tumor size, Fuhrman grade, and infiltration type were common independent prognostic factors for OS, CSS, and RFS. Conclusions: This study revealed RCC outcomes in the era of cytokine treatment for metastasis. Central pathological review is an essential component of a multicenter study with long-term follow-up. Tumor size, Fuhrman grade, and infiltration type had much greater effects than HS on survival after curative nephrectomy. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Central pathology |2 nationallicence | |
| 690 | 7 | |a Cytokine |2 nationallicence | |
| 690 | 7 | |a Histological subtypes |2 nationallicence | |
| 690 | 7 | |a Prognostic factors |2 nationallicence | |
| 690 | 7 | |a Renal cell carcinoma |2 nationallicence | |
| 700 | 1 | |a Ito |D Noriyuki |u Department of Urology, Nishi-Kobe Medical Center, 651-2273, Kobe, Japan |4 aut | |
| 700 | 1 | |a Kojima |D Shinsuke |u Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan |4 aut | |
| 700 | 1 | |a Teramukai |D Satoshi |u Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan |4 aut | |
| 700 | 1 | |a Mikami |D Yoshiki |u Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan |4 aut | |
| 700 | 1 | |a Ogawa |D Osamu |u Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan |4 aut | |
| 700 | 1 | |a Kamba |D Tomomi |u Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1161-1170 |x 1341-9625 |q 20:6<1161 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0840-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0840-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ito |D Noriyuki |u Department of Urology, Nishi-Kobe Medical Center, 651-2273, Kobe, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kojima |D Shinsuke |u Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Teramukai |D Satoshi |u Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mikami |D Yoshiki |u Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ogawa |D Osamu |u Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kamba |D Tomomi |u Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1161-1170 |x 1341-9625 |q 20:6<1161 |1 2015 |2 20 |o 10147 | ||